



From Data to Decisions: Al's Role in Modern Toxicology

Nicole C. Kleinstreuer, PhD

Director, NTP Interagency Center for the Evaluation of Alternative Toxicological Methods

Executive Director, Interagency Coordinating Committee for the Validation of Alternative Methods

National Institutes of Health • U.S. Department of Health and Human Services



Al's Role in Modern Toxicology

(As envisioned by ChatGPT4.0)





A Different Definition of Al: Augmented Intelligence



W. Ross Ashby: Intelligence Amplification (1956) J. C. R. Licklider: Man-Computer Symbiosis (1960) Douglas Engelbart: Augmenting Human Intellect (1962) The use of computational tools, information technology, and cognitive algorithms such as machine learning and artificial intelligence to **complement** and **enhance** human intelligence.







Complement-ARIE: Complement Animal Research in Experimentation

<u>**Purpose</u>**: To catalyze the development, standardization, validation and use of **human-based new approach methodologies (NAMs)** that will transform the way we do basic, translational, and clinical sciences</u>

<u>Goals</u>:

- 1. Better model and **understand human health and disease** outcomes **across diverse populations**.
- 2. Develop NAMs that **provide insight into specific biological processes** or disease states.
- 3. Validate mature NAMs to **support regulatory use** and standardization.
- 4. Complement traditional models and **make biomedical** research more efficient and effective.



Data Ecosystem



https://commonfund.nih.gov/complementarie



Build on existing NAMs activities

Digital Twin Models

Digital Twins for treatment of cancers and neuropsychiatric diseases, host-gut microbiome studies



In Silico Models

In silico and ML/AI models for neurodegenerative disease, wound healing, learning/behavior, SARS-CoV-2 propagation, many other diseases







In Chemico Screening

Tox21 high-throughput studies, biochemical assays for skin irritation, ocular toxicity

Strategic planning activities: AI-enabled Landscape Analysis

Describe existing efforts, and highlight gaps, challenges, and opportunities in the areas of human-relevant *in vitro, in chemico,* and *in silico* NAMs, and FAIRness of data resources

- Comprehensive Scientific Lit Review
 - Delivered via interactive Tableau dashboard
- Current Focal Areas
 - e.g., cell lines, organoids/MPS, AI/ML, HTS, specific disease types
- Future Directions
 - e.g., clinical translation, immune components, digital twins, combinatorial NAMs
- FAIRness of data resources
 - Application of FAIR assessment rubric to existing resources (e.g. HuBMAP = 100% FAIR)



https://commonfund.nih.gov/complementarie/strategicplanning/landscape-analysis

Complement-ARIE: Comprehensive center model



- Comprehensive centers will require embedded projects on *in vitro*, *in chemico*, and *in silico* approaches plus combinatorial approaches.
- Cores will include administrative, validation, resources, and training components.
- Phased milestone-driven projects that pilot some of the truly innovative approaches can also be transitioned for integration with the centers.

Key partners for validation networks include: ICCVAM, FDA, ICATM members, OECD, etc.



U.S. Validation Body: ICCVAM Authorization Act of 2000

PUBLIC LAW 106-545 (42 U.S.C. 285/-3)

"To establish, wherever feasible, guidelines, recommendations, and regulations that promote the regulatory acceptance of new or revised scientifically valid toxicological tests that protect human and animal health and the environment while reducing, refining, or replacing animal tests and ensuring human safety and product effectiveness."

- Consumer Product Safety Commission
- Department of Agriculture
- Department of the Interior
- Department of Transportation
- Environmental Protection Agency
- Food and Drug Administration
- Occupational Safety and Health Administration
- National Institute for Occupational Safety and Health
- Agency for Toxic Substances and Disease Registry
- National Cancer Institute



- National Inst of Environmental Health Sciences
- National Library of Medicine
- National Institutes of Health
- Department of Defense
- Department of Energy
- National Institute of Standards and Technology (since 2017)
- Dept of Veterans Affairs Office of Research and Development (since 2020)
- National Center for Advancing Translational Sciences (since 2024)

ICCVAM Co-chairs



Suzy Fitzpatrick FDA/CFSAN



Natalia Vinas DoD



Nicole Kleinstreuer Executive Director, ICCVAM Director, NICEATM

More information: <u>https://ntp.niehs.nih.gov/go/iccvam</u>

UNITED STATES ICCVAM Advancing Alternatives to Animal Testing

A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States



INTERAGENCY COORDINATING COMMITTEE ON THE VALIDATION OF ALTERNATIVE METHODS

https://ntp.niehs.nih.gov/go/natl-strategy



Connect end users with the developers of alternative methods

Establish new validation approaches that are more flexible and efficient



Ensure adoption and use of new methods by both regulators and industry



UNITED STATES ICCVAM Advancing Alternatives to Animal Testing

Interagency Coordinating Committee on the Validation of Alternative Methods

Validation, Qualification, and Regulatory Acceptance of New Approach Methodologies

March 2024





International collaborative projects

CERAPP

Collaborative Estrogen Receptor Activity Prediction Project (2015/16)

Mansouri et al. (https://doi.org/10.1289/ehp.1510267)

CoMPARA

Collaborative Modeling Project for Androgen Receptor Activity (2017/18)

Mansouri et al. (https://doi.org/10.1289/EHP5580)

CATMoS

Collaborative Acute Toxicity Modeling Suite (2019/20)

Kleinstreuer et al. (<u>https://doi.org/10.1016/j.comtox.2018.08.002</u>) Mansouri et al. (<u>https://doi.org/10.1289/EHP8495</u>) Availability of New Approach Methodologies (NAMs) in the Endocrine Disruptor Screening Program (EDSP)

December 13, 2022



EPA's Office of Chemical Safety and Pollution Prevention Office of Pesticide Programs in collaboration with Office of Research and Development





https://github.com/NIEHS/OPERA



Reference Data Variability as a Benchmark

Data-driven Confidence Intervals for Model Evaluation/Predictions



Analyzing sources of variability in acute oral toxicity data & applying 95% confidence interval to predictions

C) 5	5	50 30	00 50	00 20	00 5	000 mg/kg
VT	0	0	1	1	1	1	1
NT	1	1	1	1	1	0	0
EPA	0	0	1	1	0	0	0
GHS	0	0	<u> </u>	0	0	0	0
LD50	0	0	160 (-0	. <u>3)</u> 1 316 (+	- <u>0.3)</u> → 613	0	0
WoE	1	1	5	4	3	1	1

	Very	Toxic	Non	-Toxic	E	PA	G	HS
	Train	Eval	Train	Eval	Train	Eval	Train	Eval
Sensitivity	0.87	0.70	0.88	0.67	0.81	0.62	0.80	0.58
Specificity	0.99	0.97	0.97	0.90	0.92	0.86	0.95	0.90
Balanced Accuracy	0.93	0.84	0.92	0.78	0.87	0.74	0.88	0.74
<i>In vivo</i> Balanced Accuracy	0.	.81	0	.89	0.	82	0.	79

	LD50 values		LD50 values
	Train	Eval	In Vivo
R2	0.85	0.65	0.80
RMSE	0.30	0.49	0.42

CATMoS QSAR predictions perform just as well as replicate *in vivo* data at predicting oral acute toxicity outcome

Karmaus et al. Toxicol Sci. 2022; Mansouri et al. EHP 2021



Application of CaTMOS to Pesticide Als

EPA Case Study

- Comparative analysis of 177 pesticides with LD₅₀ data between CaTMOS and EPA database
- 88% categorical concordance for 165 chemicals with empirical *in vivo* LD₅₀ values ≥ 500 mg/kg

Toxicity Category based on CATMoS Prediction	Number of predictions	Toxi Emp I	Toxicity Category based onEmpirical In Vivo Test DataIIIIIIII		ed on Data IV
I (<50 mg/kg)	2	-	1	1	-
II (50-500 mg/kg)	25	-	6	16	3
III (>500-5,000 mg/kg)	126	-	5	62	59
IV (>5,000 mg/kg)	24	-	-	5	19
III and IV combined	150	-	5	14	45



Regulatory Toxicology and Pharmacology 149 (2024) 105614



Evaluation of *in silico* model predictions for mammalian acute oral toxicity and regulatory application in pesticide hazard and risk assessment

Patricia L. Bishop ^{a,*}, Kamel Mansouri ^b, William P. Eckel ^c, Michael B. Lowit ^c, David Allen ^{d,1}, Amy Blankinship ^c, Anna B. Lowit ^e, D. Ethan Harwood ^c, Tamara Johnson ^c, Nicole C. Kleinstreuer ^b



Bishop et al., Reg. Tox. Pharm., 2024 <u>https://doi.org/10.1016/j.yrtph.2024.105614</u>





OPERA v2.9 Models

Pł	nyschem properties	Chemicals	Version
BP	Boiling Point	7860	2.9
HL	Henry's Law Constant	2233	2.9
LogP	Octanol-water Partition Coefficient	18154	2.9
MP	Melting Point	22554	2.9
VP	Vapor Pressure	6764	2.9
WS	Water Solubility	9943	2.9
рКа	Acid Dissociation Constant	6503	2.6
KOA	Octanol/Air Partition Coefficient	270	2.6

E	Environmental fate	Chemicals	Version
AOH	Atmospheric Hydroxylation Rate	692	2.6
BCF	Bioconcentration Factor	626	2.6
BioHL	Biodegradation Half-life	150	2.6
RB	Ready Biodegradability	1603	2.6
KM	Fish Biotransformation Half-life	541	2.6
КОС	Soil Adsorption Coefficient	728	2.6

ADI	ME properties	Chemicals	Version
FUB	Fraction unbound	3229	2.8
Clint	Intrinsic clearance	1346	2.8
CACO2	Caco-2 permeability	4601	2.8

Το	cicity endpoints	Chemicals	Version
ER	Estrogen Receptor Activity	32464	2.6
AR	Androgen Receptor Activity	47673	2.6
AcuteTox	Acute Oral Systemic Toxicity	50660	2.6

	Future models
Inhalation	Acute Inhalation Systemic Toxicity
SixPack	Acute Toxicity Six-Pack Endpoints
UGT	Glucuronidation: substrate selectivity
SULT	Sulfation: substrate selectivity

https://github.com/NIEHS/OPERA

NIH

National Institute of Environmental Health Sciences

Division of Translational Toxicology

OPERA predictions online





Modeling and Visualization (MoVIZ) Pipeline





Chemical Grouping Workflow

Molecular

Descriptors

Configuration

File

Images



Moreira-Filho J.T., et al. (2024). Democratizing Cheminformatics: Interpretable Chemical Grouping Using an Automated KNIME Workflow. J. Cheminformatics. https://doi.org/10.1186/s13321-024-00894-1



Application – DTT HTS initiative





Unsupervised Clustering





Clustering and Classification Workshop



https://www.niehs.nih.gov/news /events/pastmtg/2022/nams20 22/index.cfm Convened international experts to discuss methods, their applications to guide toxicology research and inform hazard and risk assessment.

Accomplishments:

- •Defined the concept similarity for supervised and unsupervised approaches
- •Introduced different approaches, corrected some misconceptions
- Involved both NAM developers and users
 Established a consortium and a community for increasing communication and collaboration across sectors
 Ongoing and future: develop and share new ideas/concepts (best practices & innovation)

Mansouri K., et al. (2024). Unlocking the Potential of Clustering and Classification Approaches: Expert Insights and Applications. Environmental Health Perspectives. doi:10.1289/EHP14001



National Institute of Environmental Health Sciences

Division of Translational Toxicology

ICE: The Integrated Chemical Environment



Bell et al. 2017 EHP Bell et al. 2020 Tox In Vitro Abedini et al. 2021 Comp Tox Daniel et al. 2022 Front Toxicol





Toxicity endpoint	Assays	# of chemicals
Chemical Parameters	Experimental physicochemical properties	~20000
ADME Parameters	Fu, intrinsic clearance, Caco2 permeability	~3000
Acute Toxicity	In vivo acute oral, dermal, and inhalation toxicity	~10000
Cancer	In vivo and in vitro cancer, and Weight of Evidence	3038
DART	In vivo and in vitro DART	628
Skin Sensitization	In vivo and in vitro skin sensitization	1771
Skin Irritation	In vivo and in vitro skin irritation/corrosion	595
Eye Irritation	In vivo and in vitro eye irritation/corrosion	455
Endocrine	In vivo and low throughput in vitro data on AR and ER agonist and antagonist activity	384
cHTS	Curated US EPA's ToxCast and Federal Tox21 assays (in vitro)	~10000

Data



Machine Automating Study Data Curation

Identification **Extraction** Annotation Primary Source Extraction Effects Example: etuses with small ev Table location detection UMLS Vocabulary User-Defined Look-U Table structure prediction .ists: Example 68:CUI:Congenital Abnormality ocalization Postprocessing CNN Caption: Table 1, Profiles of experimental 92756 CUI Reduced (DeepPDF 58:CUI:Congenital Abnormality ALS:C0015392:CUI:Evel 50 +-UMLS code mapping MLS:C0023317:CUI:Lens, Crystalline Notes: N. number of rats. Values are mean OLPR, ODS, ORNL Text extraction OECD 74 DevTox Cross-walked Apply x to y Example: Example. Search for word matches (exact matches 074 186 66 1032.5211 r svn onvm s) Fetuses|Fetal sceral|Eye|Small abnormalities 1161.5211 Externalleye sceral|Lens

- Important for leveraging high-quality studies in the published literature
- Applications in systematic review of chemical effects
- Establishing reference datasets for validating new methods

Foster et al. 2024 Env Health Persp

Subset of UM IS codes u



Extraction workflow





Landing page and prompts



Automatic Information Extraction

ZIP File Upload

Use the file browser below to upload the data.

Size: 5.45 MB Choose File Sample_1.zip

Extraction Modes

Text Mode (Extract text from PDF)

Image Mode (Analyze PDF pages as images)

Refresh

LLM Model

GPT-4

- GPT-40 mini
- Claude 3.5 Sonnet
- Claude 3 Opus
- Claude 3 Haiku
- Llama 3.1 70B
- Llama 3.1 8B

API Key

INSERT_YOUR_API_KEY_HERE

Guide

1. File Upload

Upload a ZIP file containing the PDF files you want to process.

2. Extraction Modes

Our workflow offers two modes for extracting information from scientific publications:

- · Text Mode: Extracts the text from the PDF file and processes it using a Large Language Model (LLM) to extract the required information Image Mode: Converts PDF pages to
- images and uses a Large Language Model with vision capabilities to extract the required information.

Details

3. API Keys for LLM

Providers

Our workflow uses models from multiple providers to offer you the best possible results. You'll need to provide API keys for the respective models you select:

- · OpenAI: Powers GPT models like GPT-4o, and GPT-4o mini
- · Anthropic: Offers the models Claude 3.5 Sonnet, Claude 3 Opus, and Claude 3 Haiku · Meta: Provides free and open-source
- models Llama 3.1 70B, and Llama 3.1 8B

Details



Info Extraction - Prompt

(editable)	System prompt	User prompt - instruction	User prompt - variables
Sets the context and behavior for the Al model.	You are a scientific assistant and toxicologist expert in reviewing scientific publications and extract and analyze specific relevant information out of PDFs in valid JSON format. Be careful with numbers.	 Analyze the input JSON file (data) and extract the specified variables to create a new JSON output. Follow these guidelines: 1. Output Format: Return only a valid JSON object. Do not include any additional text before or after the JSON output. 2. JSON Structure: Each variable becomes a key-value pair in the JSON object. Use the exact variable names provided in the list below. 3. Data Handling: Use 'N/A for missing or null values. Ensure uniform formatting for similar types of variables. Include only the specified variables in the output. Combine 'specie 1' and 'specie 2' into a single 'Animal' value). 4. Value Extraction Guidelines: For Y/N' variables: 'Provide the exact relevant text snippet from the input. Specific Variable: Provide specific values or ranges (e.g., 8 weeks, '200 grams). For source text variables: Provide the exact relevant text snippet from the input. 5. Specific Variable Handling: Number of animals per treatment group': Specify as '10M and 10F or '20 overall evenly split if applicable. Dose': Include amount and units (e.g., 'Bat', 'Mouse'). Specific the axact days of administration. Complex Data Handling: Tor variables the treatment group': Specify as '10M and 10F or '20 overall evenly split if applicable. Dose': Include amount and units (e.g., '10 mg/kg'). Dose day: Specify the exact days of administration. Complex Data Handling: For variables with multiple related pieces of information, combine them into a coherent, comma-separated string. If information is single across multiple sections in the input, consolidate it into a single, comprehensive value. 1. Complex beats Handling: 6. Tor variables with multiple related pieces of information, combine them into a coherent, comma	I Title', 'Animal', 'Age at treatment (V/N)', 'Age at treatment (Entity)', 'Age at treatment (Source text)', 'Body weight at treatment? (V/N)', Body weight at treatment? (Source text)', 'Number of animals per treatment group (note if this is given as #M and #F; or # overall evenly split between the two)', Route of administration', 'Dose', Daily dosing? (V/N)', 'Dose day', 'Animal checks during treatment? (V/N)', 'Animal checks during treatment? (Source text)', Body weights during treatment? (Source text)', Body weights during treatment? (V/N)', 'Animal checks during treatment? (V/N)', 'Body weights during treatment? (V/N)', 'Body weights during treatment? (V/N)', 'Food consumption during treatment (Entity)', 'Food consumption during treatment (Entity)', 'Sacrifice (Source text)', 'Sacrifice (Source text)', 'Maternal body weight at sacrifice? (V/N)', Maternal body weight at sacrifice (Intity)', 'Feal body weight at sacrifice, individual (Source text)', 'Feal body weight at sacrifice, individual (Source text)', 'Feal body weight at sacrifice, individual (Source text)', 'Feal body weight at sacrifice, combined? (V/N)', 'Feal body weight at sacrifice, combined? (Y/N)', 'Feal body weight at sacrifice, combined? (Y/N)', 'Feal body weight at sacrifice, combined? (Y/N)', 'Feal body weight at sacrifice, combined? (Source text)', 'Feal body weight a
User Promot	ł	accuracy. 8. Error Handling and Reporting:	'Uterine weight? (Y/N)', 'Uterine weight (Entity)',
(editable)	•	 If unable to extract a value due to complexity or lack of clear information, use 'Unable to determine' instead of 'N/A'. 	'Uterine weight (Source text)', 'Organ weights? (any in addition to uterus, Y/N)', 'Organ weights? (any in addition to uterus, Y/N)',
Specific instruction you	want the	Examples of Correct Extractions:	'Organ weights? (any in addition to uterus, entity)', 'Organ weights? (any in addition to uterus, source text)', 'Pregnancy status (Y/N)'
Al to address for each c	locument	- "Animal": "Sprague-Dawley rats" - "Age at treatment (Entity)": "8-10 weeks"	'Pregnancy status (Entity)', 'Pregnancy status (Source text)'
		 Age at treatment (Entry): or 10 WERS "Body weight at treatment (Entry)": "180-220 grams" "Dose": "10 mg/kg, 50 mg/kg, 100 mg/kg" "Dose dm": "CD 6 15". 	'Number/count of live fetuses (V/N), 'Number/count of live fetuses (entity), 'Number/count of live fetuses (entity),
Guides the model in ext	tracting	- Dose day , GD 6-15 - "Number of animals per treatment group": "25 females per dose group".	'Number/count of dead fetuses? (V/N), 'Number/count of dead fetuses? (V/N),
the desired information	from the	group - "Body weight at treatment? (entity)*: "Rats: 160 g, Mice: 20 g"	'Number/count of dead fetuses (Entity), 'Number/count of dead fetuses (Source text)', 'Ental say (X/N)'
PDFs.		Variables to extract:	'Fetal sex (1/19), 'Fetal sex (Number of males and females, entity)', 'Fetal sex (Source text)',

Automatic Information Extraction

Variables to Extract (editable)

Define the specific information you want to extract from each document. Will be consistently extracted across all processed PDFs. allowing for structured data output.





National Institute of Environmental Health Sciences

Division of Translational Toxicology

Validation - precision



- Extracted if the following variables are present (Y/N), the entity, and the source text:
- Title
- Animal
- Age at treatment
- Body weight at treatment
- Number of animals per treatment group
- Route of administration
- Dose
- Daily dosing
- Dose day
- Animal checks during treatment
- Body weights during treatment
- Food consumption during treatment
- Sacrifice
- Maternal body weight at sacrifice
- · Fetal body weight at sacrifice, individual

- Fetal body weight at sacrifice, combined
 - Uterine weight
- Organ weights
- Pregnancy status
- Number of Live fetuses
- Number of Dead fetuses
- Fetal sex
- Number of Implantation sites
- Number of Corpora lutea
- Number of Resorptions
- Placental evaluation
- Fetal exam, any type
- Fetal external examination
- Fetal visceral examination
- Fetal skeletal examination







National Institute of Environmental Health Sciences Division of Translational Toxicology

E ICE Data (In Silico Models/Integrated Approaches)

Endpoint	Model	# of chemicals
Physicochemical Properties	OPEn (q)saR App (OPERA) Mansouri et al. J Cheminform 2018	1M+
Structural Properties	OPEn (q)saR App (OPERA) Mansouri et al. J Cheminform 2018	1M+
Predicted ADME Properties	OPEn (q)saR App (OPERA) Mansouri et al. J Cheminform 2018	1M+
Environmental Fate	OPEn (q)saR App (OPERA) Mansouri et al. J Cheminform 2018	1M+
Acute Oral Toxicity	Collaborative Acute Toxicity Modeling Suite (CATMoS) - Rat acute oral toxicity. Mansouri et al. EHP 2021	1M+
	Estrogen Receptor pathway Model. Browne et al. ES&T 2015	1812
Endearing	Androgen Receptor Pathway Model. Kleinstreuer et al. Chem Res Tox 2017	1855
Endochine	Collaborative Estrogen Receptor Activity Prediction Project (CERAPP). Mansouri et al. EHP 2016	1M+
	Collaborative Modeling Project for Androgen Receptor Activity (COMPARA). Mansouri et al. EHP 2020	1M+
Exposure Predictions	Systematic Empirical Evaluation of Models (US EPA'S SEEM3). Ring et al. Environ Sci Technol 2019	475,000+

Data



Accessing ICE Tools







ICE Tools: Examples







Predicting Chemical Exposure: Body Tissues, Consumer Products





National Institute of **Environmental Health Sciences**

Division of Translational Toxicology

TL

TK to Connect Metabolism and Variability





Toxicology Letters 312 (2019) 173-180

Contents lists available at ScienceDirect Toxicology Letters

Archives of	Toxicology						
https://dol.	org/10.1007/s	00204-020-0276	5-8				
тохісо	OKINETICS	AND META	BOLISM				

Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors



generic Bayesian hierarchical model for the meta-analysis of human oopulation variability in kinetics and its applications in chemical risk assessment

Witold Wiecek^{a,*}, Jean-Lou Dorne^b, Nadia Quignot^a, Camille Bechaux^c, Billy Amzal^a



Covering Phase I

CYP450 and Phase II







Interindividual differences in kinetics and polymorphisms



UGT-related uncertainty factors



Courtesy of Jean-Lou Dorne European Food Safety Authority



TK to Connect Metabolism and Variability

Inputs needed:

- Exposure (dose)
- **PBPK** parameters 2.
- Enzyme variability data 3.
- Metabolite data 4.
 - A. Structure
 - B. % Yield
 - C. Enzyme contribution



European Food Safety Authority

NIH

National Institute of Environmental Health Sciences Division of Translational Toxicology

Newly Published Whitepaper



In Silico Technologies

A STRATEGIC IMPERATIVE FOR ACCELERATING BREAKTHROUGHS AND MARKET LEADERSHIP FOR FDA-REGULATED PRODUCTS

TABLE OF CONTENTS

I.	Exe	ecutive Summary	3
II.	Intr	roduction to In Silico Technologies	4
III.	Val	ue Proposition	6
IV.	Dri	vers for Adoption	9
V.	My	ths Preventing the Adoption of In Silico Technologies.	13
VI.	In S	Silico Technologies for Evidence Generation.	16
VII.	Eco	onomic Considerations	17
	Α.	Cost and Time Benefits Gained by Adopting Regulatory Guidance	19
	B.	Cost of not harnessing ISTs Now	20
VIII.	Res	sources	21
IX.	Co	nclusion	22
Appe	endi	ces	23
	Α.	Success Stories	23
	Β.	Myths	25
	C.	Resources	28
	D	Acknowledaments	30



Acknowledgments

The NICEATM Group





Dr. Tina Morrison U.S. FDA Senior Science Advisor, Office of the Chief Scientist

UNITED STATES CCVAM Advancing Alternatives to Animal Testing







Subscribe to NICEATM News email list



Integrated Chemical Environment Now Available: 2022 – 2023 ICCVAM Biennial Report



Extra Slides



OPERA and ICE Used Worldwide



Open Access
This article is licensed under <u>CC-BY 4.0</u> (c) (r)
Article

pubs.acs.org/est

Two-Stage Machine Learning-Based Approach to Predict Points of Departure for Human Noncancer and Developmental/Reproductive Effects

Jacob Kvasnicka, Nicolò Aurisano, Kerstin von Borries, En-Hsuan Lu, Peter Fantke, Olivier Jolliet, Fred A. Wright, and Weihsueh A. Chiu*



health effects are crucial for evaluating and managing human health risks and impacts from exposure. However, PODs are unavailable for most chemicals in commerce due to a lack of *in vivo* toxicity data. We therefore developed a two-stage machine learning (ML) framework to predict human-equivalent PODs for oral exposure to organic chemicals based on chemical structure. Utilizing ML-based predictions for structural/physical/chemical/toxicological properties from OPERA 2.9 as features (Stage 1), ML models using random forest regression were trained with human-equivalent PODs derived from *in vivo* data sets for general noncancer effects (*n* = 1,791) and reproductive/developmental effects (*n* = 2,228), with robust cross-validation for feature selection and estimating



generalization errors (Stage 2). These two-stage models accurately predicted PODs for both effect categories with cross-validationbased root-mean-squared errors less than an order of magnitude. We then applied one or both models to 34,046 chemicals expected to be in the environment, revealing several thousand chemicals of *moderate* concern and several hundred chemicals of *high* concern for health effects at estimated median population exposure levels. Further application can expand by orders of magnitude the coverage of organic chemicals that can be evaluated for their human health risks and impacts.

KEYWORDS: QSAR model, machine learning, toxicity prediction, chemical risk assessment, high-throughput screening, life cycle impact assessment (LCIA)

- **OPERA** predicted properties used as features in ML model to predict PODs for thousands of chemicals
- US EPA SEEM3 exposure data downloaded from ICE to facilitate comparisons









Predicting Chemical Distribution in Brain and Adipose Compartments

Lung tissue Lung blood Q_{cardiac} Gut lumen Kgutabs Gut tissue $\mathbf{Q}_{\mathsf{gut}}$ Gut blood Q_{gut} Liver tissue Lhepatic Liver blood Arterial Blood Q_{liver} Brain tissue Venous Blood Brain blood Q_{brain} Adipose tissue Adipose $Q_{adipose}$ blood Rest of body Body blood Q_{body} Kidney tissue Kidney blood Q_{kidp} CL_{renal} Filtration

- Perfusion-limited model with brain and adipose compartments (Simple Model)
- Build upon generic PBPK model from EPA's httk R package (v2.2.2)

٠

Ongoing Updates

- Incorporation of predicted BBB permeability coefficient values in addition to measured.
- Exploration of additional validation criterions applied for other commercial brain models.
- Efforts for further comparisons using pharmacokinetic time series data from additional chemicals to provide greater confidence in these models.





In Vitro to In Vivo Extrapolation (IVIVE) for Developmental Neurotoxicity

A Comparison of Physiologically Based Pharmacokinetic Models

- Physiologically-based pharmacokinetic (PBPK) models compared for DNT-IVIVE approach
- Chemicals bioactive in DNT NAMs from EPA with experimental toxicokinetic data
- Findings
 - Chemicals preferentially partition into the brain
 - In vivo DNT points of departure fall within the range of human administered equivalent dosages (AEDs) for bioactive endpoints for both programs, showing the concordance of in vitro-derived, DNT-IVIVE predictions with in vivo data
 - GastroPlus & httk perform similarly, though httk provides somewhat more conservative estimates

Manuscript in preparation





National Institute of **Environmental Health Sciences**

Division of Translational Toxicology

Acute Inhalation Toxicity Database

Data Source	Data Records	Unique Substances
Legacy data from ChemIDplus (now integrated into PubChem)	2036	1249
National Institute for Occupational Safety and Health Pocket Guide	136	649
European Chemicals Agency Registration, Evaluation, Authorisation and Restriction of Chemicals Database	3016	611
U.S. Environmental Protection Agency Acute Exposure Guideline Levels	1682	271
U.S. Department of Defense	47	13



3Ò0

10

20

Chemical Index

30

40

100

200

Chemical Index

Database Summary

- 1025 unique chemicals
- ~760 chemicals will be used to support a collaborative modeling effort
- The database can be downloaded and explored on ICE



Download the Rat Acute Inhalation Database from ICE. https://ice.ntp.niehs.nih.gov/ DATASETDESCRIPTION

